Pharma Mar's Supplemental New Drug Application for Lung Cancer Drug Combo Gets US FDA Priority Review

Published on 06/10/2025 at 10:21

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Pharma Mar, S.A.

Pharma Mar, S.A. - Special Call	Jul. 04
Pharma Mar Ends Share Buy-Back Program, Reaches Maximum Number Of Shares	Jun. 20	RE
Pharma Mar's Supplemental New Drug Application for Lung Cancer Drug Combo Gets US FDA Priority Review	Jun. 10	MT
Pharma Mar Gets FDA Priority Review For Zepzelca And Atezolizumab Combination	Jun. 10	RE
Pharmamar Announces Positive Results from the Phase 3Imforte Study of Zepzelca®? (Lurbinectedin) in Combination with Atezolizumab	Jun. 03	CI
Pharma Mar Reports Positive Phase 3 Clinical Trial Results For Zepzelca And Atezolizumab Combination	Jun. 03	RE
Spanish stocks - Factors to watch on June 2	Jun. 02	RE
Pharma Mar Files EU Marketing Authorization Application for Small Cell Lung Cancer Treatment	May. 21	MT
Pharma Mar Submits EU MAA For Lurbinectedin In Combination With Atezolizumab For Lung Cancer	May. 21	RE
Pharma Mar's Partner Gains Argentina's Approval for Small Cell Lung Cancer Drug	May. 19	MT
Pharma Mar Says Partner Adium Pharma Received Approval For Commercialization For Zepzelca In Argentina	May. 19	RE
Pharma Mar Q1 Net Loss 3.9 Million Euros	Apr. 24	RE
Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 23	CI
Spanish stocks - Factors to watch on April 3	Apr. 03	RE
Pharma Mar Signs Licensing, Development And Commercialization Agreement With Merck For Lurbinectedin In Japan	Apr. 03	RE
PharmaMar Group's Sylentis Gets EUR21.1 Million EU Grant for Syoligo Project	Mar. 27	MT
Pharma Mar's Sylentis To Receive 21.1 Mln Euro Grant From EU For Research And Construction Of Plant	Mar. 27	RE
Pharma Mar, S.A., 2024 Earnings Call, Feb 28, 2025	Feb. 28
Pharma Mar To Carry Out Buyback Program Of Up To 9 Mln Euros	Feb. 28	RE
Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	Feb. 25	CI
Spanish stocks - Factors to watch on Feb 25	Feb. 25	RE
Pharma Mar Completes Buy-back Programme, Reaches Maximum Monetary Amount Of 5 Mln Euros	Feb. 24	RE
PharmaMar Completes Patient Enrollment for Late-stage Trial of Lung Cancer Drug	Dec. 19	MT
PharmaMar's Lung Cancer Therapy Gets Regulatory Approval in China	Dec. 03	MT
Pharma Mar, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-28	CI

PHARMA MAR, S.A.

Stock

PHM

ES0169501022

Market Closed - BME Other stock markets 11:35:15 2025-07-18 am EDT
79.05 ^EUR	-3.54%

More quotes

Chart

Duration

Period

PHM: Dynamic Chart

Income Statement and Estimates

More financial data

Headlines

Weekly market update: Earnings Wave Ahead

Ashish Kacholia and Dolly Khanna: India's Star Investors Send Portfolio Signals

July 18, 2025 at 05:13 am EDT

Employment figures offer some respite for the Bank of England

July 17, 2025 at 10:25 am EDT

Results preview: Legrand accelerates

July 17, 2025 at 05:51 am EDT

Crypto companies face the fatal trap of Bitcoin - Crypto roundup

July 17, 2025 at 05:24 am EDT

When volatility boosts US banks

July 17, 2025 at 04:42 am EDT

Shorting the dollar: the most popular trade amongst fund managers

July 17, 2025 at 03:20 am EDT

The Week's Biggest Mergers Unpacked

July 16, 2025 at 10:12 am EDT

Diageo reshuffles its management team: Nik Jhangiani temporarily replaces Debra Crew

July 16, 2025 at 09:29 am EDT

How did Indonesia go from 32% to 19% customs tariffs?

July 16, 2025 at 09:23 am EDT

All our articles